Meeting abstract
Chronic rhinosinusitis with nasal polyps and type 2 inflammation
Gorazd Poje
orcid.org/0000-0001-7159-7834
; University hospital centre Zagreb; University of Zagreb, School of medicine
Mirella Graffel
; University of Zagreb, School of Medicine
Abstract
Current treatment paradigm in chronic rhinosinusitis with nasal polyps (CRSwNP) recommends nasal
steroids and saline nasal rinses for milder cases, and oral corticosteroids and eventual surgery for severe cases.
The most common endotype of CRSwNP is type 2 inflammation. As a result of the common inflammatory
pathway type 2, CRSwNP is often associated with asthma and/or salicylate sensitivity. Classification of
chronic rhinosinusitis into different endotypes leads to more precise treatment strategies. Classification
endotypes to type 2 or non-type 2 in the future will probably be further developed for treatment purposes.
Biologic therapy focused on the pathophysiology of the underlying inflammatory disease type 2 has led to a
significant shift in the treatment options for CRSwNP, primarily for the most severe cases, refractory to
standard treatment. Our experience proved biologics effective in patients with CRSwNP to whom biologics
were prescribed because of severe asthma.
Keywords
chronic rhinosinusitis with nasal polyps, management of nasal polyps; sinus disease; type 2 inflammation
Hrčak ID:
272969
URI
Publication date:
27.2.2022.
Visits: 299 *